

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	TRASTUZUMAB EMTANSINE
PRONUNCIATION	tras tooz' oo mab em tan' seen
THERAPEUTIC CLAIM	Treatment of cancer
CHEMICAL NAMES	
1.	Immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 γ 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer, tetraamide with $N^{2'}$ -[3-[[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]- $N^{2'}$ -deacetylmaytansine
2.	Immunoglobulin G1, anti-(human receptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1, p185erbB2, MLN 19 or CD340)); humanized mouse monoclonal rhuMab HER2 γ 1 heavy chain (223-214')-disulfide with humanized mouse monoclonal rhuMab HER2 κ light chain, dimer (229-229":232-232")-bisdisulfide in which the 6-amino groups of an average of 3.5 lysine residues are amidified by 4-({3-[(3-[(1S)-2-[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxo-9,22-diazatetracyclo[19.3.1.1 ^{10,14} .0 ^{3,5}]hexacos-10,12,14(26),16,18-pentaen-6-yl]oxy}-1-methyl-2-oxoethyl)methylamino}-3-oxopropyl)sulfanyl]-2,5-dioxopyrrolidin-1-yl)methyl)cyclohexylcarbonyl groups
MOLECULAR FORMULA	$C_{6448}H_{9948}N_{1720}O_{2012}S_{44} \cdot (C_{47}H_{62}ClN_4O_{13}S)_n$
MOLECULAR WEIGHT	148.5 kDa
TRADEMARK	None as yet
MANUFACTURER	Genentech
CODE DESIGNATION	PRO132365, trastuzumab-MCC-DM1, T-DM1
<u>CAS</u> REGISTRY NUMBER	1018448-65-1